IL17A and relapsing-remitting multiple sclerosis: New research shows that LXR-mediated lipid metabolism pathways found to be dysregulated in CD4+ T cells from patients with RRMS could be fixed by stimulation with LXR-agonist GW3965 able to normalize membrane cholesterol levels, and reduced proliferation and IL17 cytokine production [66].